Adcetris 50 MG vials
Ended Awarded
- Contract number
- SPE2DB26FYM56
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $55,087
Award facts
- Contract value 100% obligated
- $55,086.73 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $55,086.73 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Adcetris 50 mg vials. This firm fixed-price delivery order, issued on November 7, 2025, with an ultimate completion date of December 2, 2025, was awarded without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The award falls under DMS Pharmaceutical Group's Indefinite Delivery Contract (IDC) with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to provide pharmaceutical products and medical consumables to Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group serves as a critical regional prime vendor contractor under the PPV-G GEN V program, which was awarded on November 13, 2025, with a ceiling value of $499,999,999 and extends through December 31, 2036. The underlying IDC establishes a 30-month base period with three 30-month option periods, enabling DLA to issue delivery orders for branded and generic prescription medications, biologics, vaccines, and medical consumables to support military healthcare operations globally. As a registered small business with the System for Award Management since 2001, DMS Pharmaceutical Group has demonstrated substantial performance across multiple therapeutic categories, including specialty oncology treatments and emergency medications, positioning it as a key supplier within the federal pharmaceutical supply chain for Department of Defense operations.
Quick answers
Who was awarded contract SPE2DB26FYM56?
SPE2DB26FYM56 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 7, 2025.
How much is contract SPE2DB26FYM56 worth?
The government has obligated $55,087 on SPE2DB26FYM56.
Is contract SPE2DB26FYM56 an order under another contract?
Yes. SPE2DB26FYM56 is a delivery order under SPE2DB22D9316, an indefinite delivery contract.
Was contract SPE2DB26FYM56 competed?
The extent of competition for SPE2DB26FYM56 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award